Biotech executive Raymond Stevens, Ph.D., recalls the public biotech market of 2013, when a lot of companies were “wondering and waiting,” biding their time and assessing their value as recovery from the 2008 housing crisis dragged on. The way he remembers it, “the market had been closed.” And now, in 2023, he sees a lot of similarities: “It’s a little bit eerie, in a way,” he told Fierce Biotech. Only six drug-developing biotechs have finalized or announced IPO plans so far this year, compared to 19 in 2022, the lowest annual total in a decade.
Read the full article: So You Think You Can Go Public? Few Biotechs Dance with Wall Street //
Source: https://www.fiercebiotech.com/biotech/so-you-think-you-can-go-public-four-biotechs-slide-wall-streets-stage-historically-sluggish